Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

129 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prediction of High Nodal Burden in Patients With Sentinel Node-Positive Luminal ERBB2-Negative Breast Cancer.
Skarping I, Bendahl PO, Szulkin R, Alkner S, Andersson Y, Bergkvist L, Christiansen P, Filtenborg Tvedskov T, Frisell J, Gentilini OD, Kontos M, Kühn T, Lundstedt D, Vrou Offersen B, Olofsson Bagge R, Reimer T, Sund M, Rydén L, de Boniface J. Skarping I, et al. Among authors: olofsson bagge r. JAMA Surg. 2024 Sep 25:e243944. doi: 10.1001/jamasurg.2024.3944. Online ahead of print. JAMA Surg. 2024. PMID: 39320882 Free PMC article.
Reply to: Pioneering combination: Nivolumab and isolated limb perfusion in melanoma in-transit metastases treatment.
Holmberg CJ, Zijlker LP, Katsarelias D, Huibers AE, Wouters MWJM, Schrage Y, Reijers SJM, van Thienen JV, Grünhagen DJ, Martner A, Nilsson JA, van Akkooi ACJ, Ny L, van Houdt WJ, Olofsson Bagge R. Holmberg CJ, et al. Among authors: olofsson bagge r. Eur J Surg Oncol. 2024 Sep 7:108653. doi: 10.1016/j.ejso.2024.108653. Online ahead of print. Eur J Surg Oncol. 2024. PMID: 39266404 No abstract available.
Completion axillary lymph node dissection for the identification of pN2-3 status as an indication for adjuvant CDK4/6 inhibitor treatment: a post-hoc analysis of the randomised, phase 3 SENOMAC trial.
de Boniface J, Appelgren M, Szulkin R, Alkner S, Andersson Y, Bergkvist L, Frisell J, Gentilini OD, Kontos M, Kühn T, Lundstedt D, Offersen BV, Olofsson Bagge R, Reimer T, Sund M, Christiansen P, Rydén L, Filtenborg Tvedskov T; SENOMAC Trialists’ Group. de Boniface J, et al. Among authors: olofsson bagge r. Lancet Oncol. 2024 Sep;25(9):1222-1230. doi: 10.1016/S1470-2045(24)00350-4. Epub 2024 Aug 6. Lancet Oncol. 2024. PMID: 39121881 Clinical Trial.
A phase Ib randomized multicenter trial of isolated hepatic perfusion in combination with ipilimumab and nivolumab for uveal melanoma metastases (SCANDIUM II trial).
Olofsson Bagge R, Nelson A, Shafazand A, Cahlin C, Carneiro A, Helgadottir H, Levin M, Rizell M, Ullenhag G, Wirén S, Lindnér P, Nilsson JA, Ny L. Olofsson Bagge R, et al. ESMO Open. 2024 Jul;9(7):103623. doi: 10.1016/j.esmoop.2024.103623. Epub 2024 Jul 2. ESMO Open. 2024. PMID: 38959698 Free PMC article. Clinical Trial.
Understanding quality of life issues in patients with advanced melanoma: Phase 1 and 2 in the development of the EORTC advanced melanoma module.
Egeler MD, van Leeuwen M, Lai-Kwon J, Eriksson H, Bartula I, Elashwah S, Fox L, Van Hemelrijck M, Jefford M, Lijnsvelt J, Bagge AL, Morag O, Ny L, Olofsson Bagge R, Rogiers A, Saw RPM, Serpentini S, Iannopollo L, Thompson J, Stiller HT, Vanlaer N, van Akkooi ACJ, van de Poll-Franse LV; EORTC Quality of Life Group. Egeler MD, et al. Among authors: olofsson bagge r. Eur J Cancer. 2024 Aug;207:114176. doi: 10.1016/j.ejca.2024.114176. Epub 2024 Jun 12. Eur J Cancer. 2024. PMID: 38875843
Quality assessment of radiotherapy in the prospective randomized SENOMAC trial.
Alkner S, Wieslander E, Lundstedt D, Berg M, Kristensen I, Andersson Y, Bergkvist L, Frisell J, Olofsson Bagge R, Sund M, Christiansen P, Davide Gentilini O, Kontos M, Kühn T, Reimer T, Rydén L, Filtenborg Tvedskov T, Vrou Offersen B, Dahl Nissen H, de Boniface J; SENOMAC Trialists’ Group. Alkner S, et al. Among authors: olofsson bagge r. Radiother Oncol. 2024 Aug;197:110372. doi: 10.1016/j.radonc.2024.110372. Epub 2024 Jun 10. Radiother Oncol. 2024. PMID: 38866204 Free article. Clinical Trial.
Tumor-infiltrating lymphocytes as a predictor of axillary and primary tumor pathological response after neoadjuvant chemotherapy in patients with breast cancer: a retrospective cohort study.
Chin K, Landén AH, Kovács A, Wärnberg F, Ekholm M, Karlsson P, Olofsson Bagge R. Chin K, et al. Among authors: olofsson bagge r. Breast Cancer Res Treat. 2024 Aug;207(1):49-63. doi: 10.1007/s10549-024-07334-6. Epub 2024 May 4. Breast Cancer Res Treat. 2024. PMID: 38703286 Free PMC article.
Omitting Axillary Dissection in Breast Cancer with Sentinel-Node Metastases.
de Boniface J, Filtenborg Tvedskov T, Rydén L, Szulkin R, Reimer T, Kühn T, Kontos M, Gentilini OD, Olofsson Bagge R, Sund M, Lundstedt D, Appelgren M, Ahlgren J, Norenstedt S, Celebioglu F, Sackey H, Scheel Andersen I, Hoyer U, Nyman PF, Vikhe Patil E, Wieslander E, Dahl Nissen H, Alkner S, Andersson Y, Offersen BV, Bergkvist L, Frisell J, Christiansen P; SENOMAC Trialists’ Group; SENOMAC Trialists' Group. de Boniface J, et al. Among authors: olofsson bagge r. N Engl J Med. 2024 Apr 4;390(13):1163-1175. doi: 10.1056/NEJMoa2313487. N Engl J Med. 2024. PMID: 38598571 Clinical Trial.
129 results